Previous 10 | Next 10 |
2023-12-18 08:17:02 ET Getaround ( GETR ) +85% . Battalion Oil Corp ( BATL ) +82% . Verrica Pharmaceuticals ( VRCA ) +62% . Cardio Diagnostics Holdings ( CDIO ) +45% . Brilliant Acquisition ( BRLI ) +45% . Northann ( ...
2023-12-15 13:25:40 ET Gainers: Getaround ( GETR ) +116% . Battalion Oil Corp ( BATL ) +82% . La Rosa Holdings Corp. ( LRHC ) +45% . Verrica Pharmaceuticals ( VRCA ) +37% . Bruush Oral Care ( BRSH ) +36% . NCS Multistage Hold...
2023-12-14 12:28:56 ET Gainers: Freight Technologies ( FRGT ) +178% . TPI Composites ( TPIC ) +67% . TriSalus Life Sciences ( TLSI ) +35% . Codexis ( CDXS ) +33% . Canterbury Park Holding Corp ( CPHC ) +33% . Canaan ( CAN ...
100% (10/10) overall response rate (ORR) and 70% (7/10) complete response (CR) rate observed in standard of care (Dara-CyBorD) relapsed/refractory AL Amyloidosis patients with median 6 lines of prior therapy in updated Phase 1/2 data as of December 10, 2023 Best responder duration of response...
2023-12-03 02:02:03 ET Summary Immix Biopharma is a biotech company focused on developing CAR-T and other cell-based therapies for cancers and heme disorders. Their most advanced project is NXC-201, a BCMA-targeted CAR-T natural killer cell therapy, which has shown a 95% overall r...
LOS ANGELES, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us”) a clinical-stage biopharmaceutical company pioneering personalized therapies for oncology and immunology, today announc...
LOS ANGELES, Nov. 22, 2023 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq:IMMX) (“ImmixBio”, “Company”, “We” or “Us”), a clinical-stage biopharmaceutical company advancing personalized therapies for oncology and immunology, today announce...
2023-11-21 11:54:51 ET More on Immix Biopharma, Inc. Immix Biopharma: A Mid-To-Late Stage CAR-T Biotech Quietly Gaining Momentum Immix Biopharma climbs on upcoming ASH readout Immix gains FDA orphan drug status for CAR-T therapy Seeking Alpha’s Quant R...
2023-11-21 11:47:03 ET More on Immix Biopharma Immix Biopharma: A Mid-To-Late Stage CAR-T Biotech Quietly Gaining Momentum Immix Biopharma climbs on upcoming ASH readout Immix gains FDA orphan drug status for CAR-T therapy Seeking Alpha’s Quant Rating ...
NEXICART-2 to expand studies of NXC-201 in relapsed/refractory AL Amyloidosis to U.S. sites based on IND clearance 72 patients previously dosed with NXC-201 ex-U.S. First CAR-T program for light-chain (AL) Amyloidosis Favorable tolerability enables expansion into autoimmune indication...
News, Short Squeeze, Breakout and More Instantly...
LOS ANGELES, CA, July 25, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us”, “IMMX”) (Nasdaq: IMMX), a clinical-stage biopharmaceutical company trailblazing cell therapies in AL Amyloidosis and...
Lead site Memorial Sloan Kettering Cancer Center (MSKCC) Timing of milestone in-line with mid-2024 guidance Data from ex-US clinical trial reported at ASGCT 2024 showed a 92% overall response rate LOS ANGELES, July 08, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio...
A look at the top 10 most actives in the United States NVIDIA Corporation (NVDA) rose 4.6% to $128.28 on volume of 215,349,874 shares Zoomcar Holdings Inc. (ZCAR) rose 34.0% to $0.183 on volume of 204,010,215 shares Maxeon Solar Technologies Ltd. (MAXN) fell 3.5% to $0.1736 on volume of 2...